source
- MapLight shifts focus to schizophrenia drug after mixed Phase 2 results, raises $150 millionMapLight Therapeutics reported mixed outcomes from its Phase 2 Zephyr trial of the muscarinic agonist ML-007C-MA. A twice‑daily dose achieved the study’s primary endpoint with notable reductions in…
- Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board→ Some big changes are coming at Bicara Therapeutics, and it starts at the top. President and COO Ryan Cohlhepp will take over as CEO on Jan. 1, and Claire Mazumdar ...Endpoints · 34m ago↗ source